Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition

Go back to Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition
Harmony Metals, Inc. Common (NASDAQ: HRMY) Delayed: 42.10 +0.08 (0.19%)
Previous Close $42.02    52 Week High $1.35 
Open $41.87    52 Week Low $0.10 
Day High $42.52    P/E N/A 
Day Low $41.20    EPS $0.00 
Volume 839,025